Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Primary Care
Published in: BMC Primary Care 1/2021

Open Access 01-12-2021 | Chronic Obstructive Lung Disease | Review

COPD – do the right thing

Authors: Hanna Sandelowsky, Ulla Møller Weinreich, Bernt B. Aarli, Josefin Sundh, Kristian Høines, Georgios Stratelis, Anders Løkke, Christer Janson, Christian Jensen, Kjell Larsson

Published in: BMC Primary Care | Issue 1/2021

Login to get access

Abstract

A gap exists between guidelines and real-world clinical practice for the management and treatment of chronic obstructive pulmonary disease (COPD). Although this has narrowed in the last decade, there is room for improvement in detection rates, treatment choices and disease monitoring. In practical terms, primary care practitioners need to become aware of the huge impact of COPD on patients, have non-judgemental views of smoking and of COPD as a chronic disease, use a holistic consultation approach and actively motivate patients to adhere to treatment.
This article is based on discussions at a virtual meeting of leading Nordic experts in COPD (the authors) who were developing an educational programme for COPD primary care in the Nordic region. The article aims to describe the diagnosis and lifelong management cycle of COPD, with a strong focus on providing a hands-on, practical approach for medical professionals to optimise patient outcomes in COPD primary care.
Literature
1.
2.
Diab N, Gershon AS, Sin DD, Tan WC, Bourbeau J, Boulet LP, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(9):1130–9.PubMedCrossRef
3.
4.
Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–45.PubMedPubMedCentral
5.
6.
Löfdahl CG, Tilling B, Ekström T, Jörgensen L, Johansson G, Larsson K. COPD health care in Sweden - a study in primary and secondary care. Respir Med. 2010;104(3):404–11.PubMedCrossRef
7.
Perez X, Wisnivesky JP, Lurslurchachai L, Kleinman LC, Kronish IM. Barriers to adherence to COPD guidelines among primary care providers. Respir Med. 2012;106(3):374–81.PubMedCrossRef
8.
Ställberg B, Janson C, Johansson G, Larsson K, Stratelis G, Telg G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1):38–45.PubMedCrossRef
9.
Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2001;18(6):903–8.PubMedCrossRef
10.
Arne M, Emtner M, Lisspers K, Wadell K, Ställberg B. Availability of pulmonary rehabilitation in primary care for patients with COPD: a cross-sectional study in Sweden. Eur Clin Respir J. 2016;3:31601.PubMedCrossRef
11.
Jones RCM, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014;2(4):267–76.PubMedCrossRef
12.
Rothnie KJ, Chandan JS, Goss HG, Mullerova H, Quint JK. Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1663–8.PubMedPubMedCentralCrossRef
13.
Heffler E, Crimi C, Mancuso S, Campisi R, Puggioni F, Brussino L, et al. Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients. Respir Med. 2018;142:48–52.PubMedCrossRef
14.
Ragaišienė G, Kibarskyte R, Gauronskaite R, Giedraityte M, Dapsauskaite A, Kasiulevicius V, et al. Diagnosing COPD in primary care: what has real life practice got to do with guidelines? Multidiscip Respir Med. 2019;14:28.PubMedPubMedCentralCrossRef
15.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.PubMedCrossRef
16.
James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1789–858.CrossRef
17.
Ställberg B, Janson C, Larsson K, Johansson G, Kostikas K, Gruenberger JB, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33.PubMedPubMedCentralCrossRef
18.
Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:95–109.PubMedPubMedCentral
19.
van der Molen T, Miravitlles M, Kocks JWH. COPD management: role of symptom assessment in routine clinical practice. Int J Chron Obstruct Pulmon Dis. 2013;8:461–71.PubMedPubMedCentralCrossRef
20.
21.
22.
Weiss ST, DeMeo DL, Postma DS. COPD: problems in diagnosis and measurement. Eur Respir J Suppl. 2003;21:4s–12s.CrossRef
23.
Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894–900.PubMedCrossRef
24.
Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573–81.PubMedPubMedCentral
25.
Sandelowsky H, Ställberg B, Nager A, Hasselström J. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case finding study. BMC Fam Pract. 2011;12:122.PubMedPubMedCentralCrossRef
26.
27.
Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40(5):1115–22.PubMedCrossRef
28.
Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262–72.PubMedCrossRef
29.
Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):160113.PubMedCrossRef
30.
van den Boom G, Rutten-van Mölken MP, Tirimanna PR, van Schayck CP, Folgering H, van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J. 1998;11(1):67–72.PubMedCrossRef
31.
Ofir D, Laveneziana P, Webb KA, Lam YM, O’Donnell DE. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(6):622–9.PubMedCrossRef
32.
Al Talag A, Wilcox P. Clinical physiology of chronic obstructive pulmonary disease. BCMJ. 2008;50(2):97–102.
33.
O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD. 2007;4(3):225–36.PubMedCrossRef
34.
O'Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(2):180–4.PubMedCrossRef
35.
Watz H, Pitta F, Rochester CL, Garcia-Aymerich J, ZuWallack R, Troosters T, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521–37.PubMedCrossRef
36.
Okajima Y, Come CE, Nardelli P, Sonavane SK, Yen A, Nath HP, et al. Luminal plugging on chest CT scan: association with lung function, quality of life, and COPD clinical phenotypes. Chest. 2020;158(1):121–30.PubMedPubMedCentralCrossRef
37.
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–53.PubMedCrossRef
38.
Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–40.PubMedCrossRef
39.
Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The dyspnoea, obstruction, smoking, exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J. 2012;21(3):295–301.PubMedPubMedCentralCrossRef
40.
Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(6):591–7.PubMedCrossRef
41.
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27.PubMedCrossRef
42.
Baraldo S, Turato G, Saetta M. Pathophysiology of the small airways in chronic obstructive pulmonary disease. Respiration. 2012;84(2):89–97.PubMedCrossRef
43.
Rossi A, Aisanov Z, Avdeev S, Di Maria G, Donner CF, Izquierdo JL, et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir Med. 2015;109(7):785–802.PubMedCrossRef
44.
45.
Kupper N, Bonhof C, Westerhuis B, Widdershoven J, Denollet J. Determinants of dyspnea in chronic heart failure. J Card Fail. 2016;22(3):201–9.PubMedCrossRef
46.
Jenkins CR, Celli B, Anderson JA, Ferguson GT, Jones PW, Vestbo J, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38–45.PubMedCrossRef
47.
Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25(8):2043–8.PubMedCrossRef
48.
Braghiroli A, Braido F, Piraino A, Rogliani P, Santus P, Scichilone N. Day and night control of COPD and role of pharmacotherapy: a review. Int J Chron Obstruct Pulmon Dis. 2020;15:1269–85.PubMedPubMedCentralCrossRef
49.
van Buul AR, Kasteleyn MJ, Chavannes NH, Taube C. Association between morning symptoms and physical activity in COPD: a systematic review. Eur Respir Rev. 2017;26(143):160033.PubMedCrossRef
50.
Singh D, Miravitlles M, Vogelmeier C. Chronic obstructive pulmonary disease individualized therapy: tailored approach to symptom management. Adv Ther. 2017;34(2):281–99.PubMedCrossRef
51.
52.
Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–92.PubMedCrossRef
53.
Wang M, Aaron CP, Madrigano J, Hoffman EA, Angelini E, Yang J, et al. Association between long-term exposure to ambient air pollution and change in quantitatively assessed emphysema and lung function. JAMA. 2019;322(6):546–56.PubMedPubMedCentralCrossRef
54.
Balcan B, Akan S, Ugurlu AO, Handemir BO, Ceyhan BB, Ozkaya S. Effects of biomass smoke on pulmonary functions: a case control study. Int J Chron Obstruct Pulmon Dis. 2016;11:1615–22.PubMedPubMedCentralCrossRef
55.
Po JYT, FitzGerald JM, Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax. 2011;66(3):232–9.PubMedCrossRef
56.
Bergdahl IA, Torén K, Eriksson K, Hedlund U, Nilsson T, Flodin R, et al. Increased mortality in COPD among construction workers exposed to inorganic dust. Eur Respir J. 2004;23(3):402–6.PubMedCrossRef
57.
Humerfelt S, Gulsvik A, Skjærven R, Nilssen S, Kvåle G, Sulheim O, et al. Decline in FEV1 and airflow limitation related to occupational exposures in men of an urban community. Eur Respir J. 1993;6(8):1095–103.PubMedCrossRef
58.
Burney P, Jithoo A, Kato B, Janson C, Mannino D, Niżankowska-Mogilnicka E, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. Thorax. 2014;69(5):465–73.PubMedCrossRef
59.
Cosio Piqueras MG, Cosio MG. Disease of the airways in chronic obstructive pulmonary disease. Eur Respir J. 2001;34(34 suppl):41s–9s.CrossRef
60.
Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–92.PubMedCrossRef
61.
Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–49.PubMedPubMedCentralCrossRef
62.
63.
64.
Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–13.PubMedCrossRef
65.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80.PubMedCrossRef
66.
67.
Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(41):46s–53s.CrossRef
68.
69.
70.
Singh D, D'Urzo AD, Donohue JF, Kerwin EM. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respir Res. 2019;20(1):141.PubMedPubMedCentralCrossRef
71.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.PubMedCrossRef
72.
Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.PubMedPubMedCentralCrossRef
73.
Halpin DMG, Decramer M, Celli BR, Mueller A, Metzdorf N, Tashkin DP. Effect of a single exacerbation on decline in lung function in COPD. Respir Med. 2017;128:85–91.PubMedCrossRef
74.
Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, et al. Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial. Respir Res. 2018;19(1):251.PubMedPubMedCentralCrossRef
75.
Roche N, Wedzicha JA, Patalano F, Frent SM, Larbig M, Shen S, et al. COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study. Eur Respir J. 2017;50:OA1487.
76.
Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.PubMedCrossRef
77.
Halpin DMG, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:653–61.PubMedPubMedCentralCrossRef
78.
Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–7.PubMedCrossRef
79.
Halpin DMG, Decramer M, Celli B, Kesten S, Leimer I, Tashkin DP. Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011;189(4):261–8.PubMedPubMedCentralCrossRef
80.
Rothnie KJ, Yan R, Smeeth L, Quint JK. Risk of myocardial infarction (MI) and death following MI in people with chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis. BMJ Open. 2015;5(9):e007824.PubMedPubMedCentralCrossRef
81.
Rothnie KJ, Connell O, Müllerová H, Smeeth L, Pearce N, Douglas I, et al. Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2018;15(8):935–46.PubMedPubMedCentralCrossRef
82.
Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.PubMedCrossRef
83.
Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl. 2):398S–401S.PubMedCrossRef
84.
Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–71.PubMedPubMedCentralCrossRef
85.
Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–31.PubMedPubMedCentralCrossRef
86.
Ho T-W, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ, et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One. 2014;9(12):e114866.PubMedPubMedCentralCrossRef
87.
Lindenauer PK, Dharmarajan K, Qin L, Lin Z, Gershon AS, Krumholz HM. Risk trajectories of readmission and death in the first year after hospitalization for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;197(8):1009–17.PubMedPubMedCentralCrossRef
88.
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–15.PubMedCrossRef
89.
Spencer S, Jones PW, Globe Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58(7):589–93.PubMedPubMedCentralCrossRef
90.
Cao Y-Q, Dong L-X, Cao J. Pulmonary embolism in patients with acute exacerbation of chronic obstructive pulmonary disease. Chin Med J. 2018;131(14):1732–7.PubMedPubMedCentralCrossRef
91.
Wang M, Lin EP, Huang LC, Li CY, Shyr Y, Lai CH. Mortality of cardiovascular events in patients with COPD and preceding hospitalization for acute exacerbation. Chest. 2020;158(3):973–85.PubMedCrossRef
92.
Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–7.PubMedPubMedCentralCrossRef
93.
Connors AF Jr, Dawson NV, Thomas C, Harrell FE, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med. 1996;154(4 Pt 1):959–67.PubMedCrossRef
94.
Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000;117(5 Suppl. 2):380s–5s.PubMedCrossRef
95.
Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129(2):317–24.PubMedCrossRef
96.
Barnes N, Calverley PMA, Kaplan A, Rabe KF. Chronic obstructive pulmonary disease and exacerbations: patient insights from the global hidden depths of COPD survey. BMC Pulm Med. 2013;13:54.PubMedPubMedCentralCrossRef
97.
Janson C, Nwaru BI, Wiklund F, Telg G, Ekström M. Management and risk of mortality in patients hospitalised due to a first severe COPD exacerbation. Int J Chron Obstruct Pulmon Dis. 2020;15:2673–82.PubMedPubMedCentralCrossRef
98.
Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(12):1298–303.PubMedCrossRef
99.
Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177(4):396–401.PubMedCrossRef
100.
Xu W, Collet J-P, Shapiro S, Lin Y, Yang T, Wang C, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J. 2010;35(5):1022–30.PubMedCrossRef
101.
Sandelowsky H, Krakau I, Modin S, Ställberg B, Nager A. COPD patients need more information about self-management: a cross-sectional study in Swedish primary care. Scand J Prim Health Care. 2019;37(4):459–67.PubMedPubMedCentralCrossRef
102.
Guerra B, Gaveikaite V, Bianchi C, Puhan MA. Prediction models for exacerbations in patients with COPD. Eur Respir Rev. 2017;26(143):160061.PubMedCrossRef
103.
Hoogendoorn M, Feenstra TL, Boland M, Briggs AH, Borg S, Jansson S-A, et al. Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. Int J Chron Obstruct Pulmon Dis. 2017;12:3183–94.PubMedPubMedCentralCrossRef
104.
Rassouli F, Baty F, Stolz D, Albrich WC, Tamm M, Widmer S, et al. Longitudinal change of COPD assessment test (CAT) in a telehealthcare cohort is associated with exacerbation risk. Int J Chron Obstruct Pulmon Dis. 2017;12:3103–9.PubMedPubMedCentralCrossRef
105.
Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest. 2011;140(3):626–33.PubMedPubMedCentralCrossRef
106.
Pavord ID, Jones PW, Burgel P-R, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec. Iss):21–30.PubMedPubMedCentral
107.
Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–74.PubMedCrossRef
108.
Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–73.PubMedCrossRef
109.
Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–51.PubMedCrossRef
110.
Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2008;3(4):693–9.PubMedPubMedCentral
111.
Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Mørkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–22.PubMedCrossRef
112.
Abramson MJ, Schattner RL, Sulaiman ND, Del Colle EA, Aroni R, Thien F. Accuracy of asthma and COPD diagnosis in Australian general practice: a mixed methods study. Prim Care Respir J. 2012;21(2):167–73.PubMedPubMedCentralCrossRef
113.
Eaton T, Withy S, Garrett JE, Mercer J, Whitlock RM, Rea HH. Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest. 1999;116(2):416–23.PubMedCrossRef
114.
Hangaard S, Helle T, Nielsen C, Hejlesen OK. Causes of misdiagnosis of chronic obstructive pulmonary disease: a systematic scoping review. Respir Med. 2017;129:63–84.PubMedCrossRef
115.
Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999;115(4):966–71.PubMedCrossRef
116.
Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J. 2008;31(4):742–50.PubMedCrossRef
117.
Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest. 2004;126(2 Suppl):125S–37S discussion 59S-61S.PubMedCrossRef
118.
Janson C, Malinovschi A, Amaral AFS, Accordini S, Bousquet J, Buist AS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J. 2019;54(3):1900561.PubMedCrossRef
119.
Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax. 2003;58(8):659–64.PubMedPubMedCentralCrossRef
120.
Kerstjens HAM, Brand PL, Quanjer PH, van der Bruggen-Bogaarts BA, Koëter GH, Postma DS. Variability of bronchodilator response and effects of inhaled corticosteroid treatment in obstructive airways disease. Dutch CNSLD Study Group. Thorax. 1993;48(7):722–9.PubMedPubMedCentralCrossRef
121.
Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, et al. Defining the “frequent exacerbator” phenotype in COPD: a hypothesis-free approach. Chest. 2018;153(5):1106–15.PubMedCrossRef
122.
Corlateanu A, Mendez Y, Wang Y, Garnica RJA, Botnaru V, Siafakas N. Chronic obstructive pulmonary disease and phenotypes: a state-of-the-art. Pulmonology. 2020;26(2):95–100.PubMedCrossRef
123.
Sandelowsky H, Hylander I, Krakau I, Modin S, Ställberg B, Nager A. Time pressured deprioritization of COPD in primary care: a qualitative study. Scand J Prim Health Care. 2016;34(1):55–65.PubMedPubMedCentralCrossRef
124.
Larsson K, Janson C, Ställberg B, Lisspers K, Olsson P, Kostikas K, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:995–1008.PubMedPubMedCentralCrossRef
125.
Spruit MA, Polkey MI, Celli B, Edwards LD, Watkins ML, Pinto-Plata V, et al. Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease. J Am Med Dir Assoc. 2012;13(3):291–7.PubMedCrossRef
126.
Moy ML, Gould MK, Liu I-LA, Lee JS, Nguyen HQ. Physical activity assessed in routine care predicts mortality after a COPD hospitalisation. ERJ Open Res. 2016;2(1):00062–2015.PubMedPubMedCentralCrossRef
127.
Yawn BP. Differential assessment and management of asthma vs chronic obstructive pulmonary disease. Medscape J Med. 2009;11(1):20.PubMedPubMedCentral
128.
129.
de Miguel Díez J, Chancafe Morgan J, Jiménez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis. 2013;8:305–12.PubMedPubMedCentralCrossRef
130.
Dou S, Zheng C, Ji X, Wang W, Xie M, Cui L, et al. Co-existence of COPD and bronchiectasis: a risk factor for a high ratio of main pulmonary artery to aorta diameter (PA:A) from computed tomography in COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:675–81.PubMedPubMedCentralCrossRef
131.
Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J. 2007;29(5):923–9.PubMedCrossRef
132.
Criner RN, Hatt CR, Galban CJ, Kazerooni EA, Lynch DA, McCormack MC, et al. Relationship between diffusion capacity and small airway abnormality in COPDGene. Respir Res. 2019;20(1):269.PubMedPubMedCentralCrossRef
133.
McCormack MC, Enright PL. Making the diagnosis of asthma. Respir Care. 2008;53(5):583–90.PubMed
134.
Kim V, Aaron SD. What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement. Eur Respir J. 2018;52(5):1801261.PubMedCrossRef
135.
Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):543–8.PubMedPubMedCentralCrossRef
136.
137.
Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–61.PubMedCrossRef
138.
Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006;28(6):1245–57.PubMedCrossRef
139.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.PubMedCrossRef
140.
Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VP, Bruijnzeel PL, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.PubMedCrossRef
141.
Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–12.PubMedCrossRef
142.
Ellingsen J, Johansson G, Larsson K, Lisspers K, Malinovschi A, Ställberg B, et al. Impact of comorbidities and commonly used drugs on mortality in COPD - real-world data from a primary care setting. Int J Chron Obstruct Pulmon Dis. 2020;15:235–45.PubMedPubMedCentralCrossRef
143.
144.
Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25(12):1209–21.PubMedCrossRef
145.
Marsh S, Guck TP. Anxiety and depression: easing the burden in COPD patients. J Fam Pract. 2016;65(4):246–56.PubMed
146.
Sikjær MG, Løkke A, Hilberg O. The influence of psychiatric disorders on the course of lung cancer, chronic obstructive pulmonary disease and tuberculosis. Respir Med. 2018;135:35–41.PubMedCrossRef
147.
Sundh J, Lindgren H, Hasselgren M, Montgomery S, Janson C, Ställberg B, et al. Pulmonary rehabilitation in COPD – available resources and utilization in Swedish primary and secondary care. Int J Chron Obstruct Pulmon Dis. 2017;12:1695–704.PubMedPubMedCentralCrossRef
148.
Rogliani P, Calzetta L, Braido F, Cazzola M, Clini E, Pelaia G, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:3115–30.PubMedPubMedCentralCrossRef
149.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–58.PubMedCrossRef
150.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–84.PubMedCrossRef
151.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.PubMedCrossRef
152.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–26.PubMedCrossRef
153.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–56.PubMedCrossRef
154.
Martinez FJ, Ferguson GT, Bourne E, Ballal S, Darken P, Aurivillius M, et al. Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler improves exacerbation outcomes in patients with COPD without a recent exacerbation history: a subgroup analysis of KRONOS. Int J Chron Obstruct Pulmon Dis. 2021;16:179–89.PubMedPubMedCentralCrossRef
155.
Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;(10):CD009764.
156.
Ni W, Shao X, Cai X, Wei C, Cui J, Wang R, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):e0121257.PubMedPubMedCentralCrossRef
157.
Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681–6.
158.
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med. 1980;93(3):391–8.
159.
Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177–86.PubMedPubMedCentralCrossRef
160.
Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.PubMedCrossRef
161.
Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26.PubMedCrossRef
162.
Soriano JB, Kiri VA, Pride NB, Vestbo J. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med. 2003;2(1):67–74.PubMedCrossRef
163.
Briggs AH, Lozano-Ortega G, Spencer S, Bale G, Spencer MD, Burge PS. Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. Value Health. 2006;9(4):227–35.PubMedCrossRef
164.
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med. 2021;203(5):553–64.PubMedPubMedCentralCrossRef
165.
LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282(24):2340–6.PubMedCrossRef
166.
Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
167.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383–9.
168.
Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–53.CrossRef
169.
Janson C, Johansson G, Ställberg B, Lisspers K, Olsson P, Keininger DL, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res. 2018;19(1):172.PubMedPubMedCentralCrossRef
170.
Watz H, Tetzlaff K, Wouters EFM, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–8.PubMedCrossRef
171.
Oshagbemi OA, Franssen FME, van Kraaij S, Braeken DCW, Wouters EFM, Maitland-van der Zee AH, et al. Blood eosinophil counts, withdrawal of inhaled corticosteroids and risk of COPD exacerbations and mortality in the Clinical Practice Research Datalink (CPRD). COPD. 2019;16(2):152–9.PubMedCrossRef
172.
Agusti A, Alcazar B, Cosio B, Echave JM, Faner R, Izquierdo JL, et al. Time for a change: anticipating the diagnosis and treatment of COPD. Eur Respir J. 2020;56(1):2002104.PubMedCrossRef
173.
Au DH, Bryson CL, Chien JW, Sun H, Udris EM, Evans LE, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24(4):457–63.PubMedPubMedCentralCrossRef
174.
van Eerd EAM, van der Meer RM, van Schayck OCP, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;2016(8):CD010744.PubMedCentral
175.
McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793.
176.
Waschki B, Spruit MA, Watz H, Albert PS, Shrikrishna D, Groenen M, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med. 2012;106(4):522–30.PubMedCrossRef
177.
Donaire-Gonzalez D, Gimeno-Santos E, Balcells E, de Batlle J, Ramon MA, Rodriguez E, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46(5):1281–9.PubMedCrossRef
178.
Waschki B, Kirsten AM, Holz O, Mueller K-C, Schaper M, Sack A-L, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(3):295–306.PubMedCrossRef
179.
Waschki B, Kirsten A, Holz O, Müller K-C, Meyer T, Watz H, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–42.PubMedCrossRef
180.
Troosters T, van der Molen T, Polkey M, Rabinovich RA, Vogiatzis I, Weisman I, et al. Improving physical activity in COPD: towards a new paradigm. Respir Res. 2013;14:115.PubMedPubMedCentralCrossRef
181.
Demeyer H, Louvaris Z, Frei A, Rabinovich RA, de Jong C, Gimeno-Santos E, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial. Thorax. 2017;72(5):415–23.PubMedCrossRef
182.
Cranston JM, Crockett A, Moss J, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;2005(4):CD001744.PubMedCentral
183.
Group L-TOTTR. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med. 2016;375(17):1617–27.CrossRef
184.
Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–8.PubMedCrossRef
185.
Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532.PubMedPubMedCentralCrossRef
186.
187.
Morrison D, Agur K, Mercer S, Eiras A, González-Montalvo JI, Gruffydd-Jones K. Managing multimorbidity in primary care in patients with chronic respiratory conditions. NPJ Prim Care Respir Med. 2016;26:16043.PubMedPubMedCentralCrossRef
188.
Lindh A, Theander K, Arne M, Lisspers K, Lundh L, Sandelowsky H, et al. Errors in inhaler use related to devices and to inhalation technique among patients with chronic obstructive pulmonary disease in primary health care. Nurs Open. 2019;6(4):1519–27.PubMedPubMedCentralCrossRef
189.
Fletcher MJ, Dahl BH. Expanding nurse practice in COPD: is it key to providing high quality, effective and safe patient care? Prim Care Respir J. 2013;22(2):230–3.PubMedPubMedCentralCrossRef
190.
Lisspers K, Johansson G, Jansson C, Larsson K, Stratelis G, Hedegaard M, et al. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. Respir Med. 2014;108(9):1345–54.PubMedCrossRef
191.
British Thoracic Society Standards of Care Committee. BTS statement on criteria for specialist referral, admission, discharge and follow-up for adults with respiratory disease. Thorax. 2008;63(Suppl. 1):i1–i16.CrossRef
Metadata
Title
COPD – do the right thing
Authors
Hanna Sandelowsky
Ulla Møller Weinreich
Bernt B. Aarli
Josefin Sundh
Kristian Høines
Georgios Stratelis
Anders Løkke
Christer Janson
Christian Jensen
Kjell Larsson
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2021
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-021-01583-w

Other articles of this Issue 1/2021

BMC Primary Care 1/2021 Go to the issue

Research article

Characteristics of patients who access zero, one or multiple general practices and reasons for their choices: a study in regional Australia

Research article

Reducing prescribing of benzodiazepines in older adults: a comparison of four physician-focused interventions by a medical regulatory authority

Research

“I must, and I can live with that”: a thematic analysis of patients’ perspectives on polypharmacy and a digital decision support system for GPs

Research

Doctor-patient communication skills: a survey on knowledge and practice of Iranian family physicians

Correction

Correction to: Characteristics of a COVID-19 confirmed case series in primary care (COVID-19-PC project): a cross-sectional study

Research

What role conceptions do multi-healthcare professionals have of physicians and what role expectation do they have of physicians in a community?